数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Ashleigh Palmer Co-Founder, President and Chief Executive Officer,Director 58 200.79万美元 未持股 2021-03-01
Jeffrey Bluestone Director 67 20.99万美元 未持股 2021-03-01
Avery Catlin Director 72 23.09万美元 未持股 2021-03-01
Sean Doherty Director 52 21.95万美元 未持股 2021-03-01
John Jenkins Director 63 108.00万美元 未持股 2021-03-01
Wayne Pisano Chairman 66 26.19万美元 未持股 2021-03-01
Nancy Wysenski Director 63 130.60万美元 未持股 2021-03-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Ashleigh Palmer Co-Founder, President and Chief Executive Officer,Director 58 200.79万美元 未持股 2021-03-01
Andrew Drechsler Chief Financial Officer 49 172.32万美元 未持股 2021-03-01
Francisco Leon Co-Founder, Chief Scientific Officer 49 173.68万美元 未持股 2021-03-01
Eleanor Ramos Chief Medical Officer 64 176.94万美元 未持股 2021-03-01
Jason Hoitt Chief Commercial Officer 43 559.99万美元 未持股 2021-03-01
Heidy King Jones Chief Legal Officer 38 未披露 未持股 2021-03-01

董事简历

中英对照 |  中文 |  英文
Ashleigh Palmer

Ashleigh Palmer是ProVention的联合创始人,自2016年成立以来一直担任我们的总裁兼首席执行官,并担任董事会成员。Palmer先生目前担任Third Pole的董事会非执行董事,该公司是一家临床阶段的生物制药公司,为某些危及生命和使人衰弱的重症监护和慢性心肺疾病开发电动产生的吸入一氧化氮。Palmer先生也是Creative BioVentures™;Corp.的总裁。CBV,一家服务于生物制药行业的战略咨询公司。自2002年创立CBV以来,Palmer先生为众多客户提供企业定位和战略,资金筹集,并购交易,临床开发和商业化方面的建议,并为公共和私人生物制药公司承担了许多首席执行官和董事会级别的转型领导和周转任务。2015年至2017年,Palmer先生担任Celimmune,LLC(一家临床开发阶段的免疫疗法公司,致力于开发腹腔疾病和难治性腹腔疾病的疗法)的执行主席。Celimmune于2017年11月被安进公司收购。Palmer从2010年到2013年7月担任Unigene Laboratories,Inc.(一家生物制药公司)首席执行官,负责Unigene&8217;s债务的重大重组。债务人收购了Unigene几乎所有的资产后,Unigene于2013年7月申请破产。在创立Celimmune和CBV之前,帕尔默先生Vice President British Oxygen&8217;S Ohmeda Pharmaceutical Products,Inc.的业务开发,在该公司将其出售给百特国际有限公司领导的财团方面发挥了重要作用,他将该公司的吸入一氧化氮资产剥离为INO Therapeutics,Inc.(现为Ikaria/Mallinckrodt)。在他的领导下,作为创始总裁兼首席执行官,INO Therapeutics开发并商业化了世界上第一种选择性肺血管扩张剂Inomax&174;,建立了基于时间的定价,孤儿药专营权,随后于2015年被Mallinckrodt以23亿美元收购。在其职业生涯早期,Palmer先生在Reckitt Benckiser担任越来越重要的销售与市场营销领导职务。Palmer先生在布拉德福德大学(University of Bradford)获得工商管理硕士学位,并获得理学学士学位。the University of Manchester生物化学和应用分子生物学荣誉。


Ashleigh Palmer is a co-founder of Provention and has served as our President and Chief Executive Officer “CEO” and on the board of directors since inception in 2016. Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions, a role he has held from 2014 to 2020. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry. Since founding CBV in 2002 Mr. Palmer has advised numerous clients regarding corporate positioning and strategy, fund raising, merger and acquisition transactions, clinical development and commercialization, and has undertaken a number of CEO and board level transformational leadership and turnaround assignments for both public and private biopharma companies. From 2015 through 2017 Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing therapies for celiac disease and refractory celiac disease. Celimmune was acquired by Amgen Inc. in November 2017. Mr. Palmer served as Chief Executive Officer of Unigene Laboratories, Inc., a biopharmaceutical company, from 2010 to July 2013 in conjunction with a substantial restructuring of Unigene’s debt. Following the debtholder’s acquisition of substantially all of Unigene’s assets, Unigene filed for bankruptcy in July 2013. Prior to founding Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, establishing a time-based pricing, orphan drug franchise, subsequently acquired by Mallinckrodt in 2015 for $2.3 billion. Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Mr. Palmer received his MBA from the University of Bradford and his B.Sc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester.
Ashleigh Palmer是ProVention的联合创始人,自2016年成立以来一直担任我们的总裁兼首席执行官,并担任董事会成员。Palmer先生目前担任Third Pole的董事会非执行董事,该公司是一家临床阶段的生物制药公司,为某些危及生命和使人衰弱的重症监护和慢性心肺疾病开发电动产生的吸入一氧化氮。Palmer先生也是Creative BioVentures™;Corp.的总裁。CBV,一家服务于生物制药行业的战略咨询公司。自2002年创立CBV以来,Palmer先生为众多客户提供企业定位和战略,资金筹集,并购交易,临床开发和商业化方面的建议,并为公共和私人生物制药公司承担了许多首席执行官和董事会级别的转型领导和周转任务。2015年至2017年,Palmer先生担任Celimmune,LLC(一家临床开发阶段的免疫疗法公司,致力于开发腹腔疾病和难治性腹腔疾病的疗法)的执行主席。Celimmune于2017年11月被安进公司收购。Palmer从2010年到2013年7月担任Unigene Laboratories,Inc.(一家生物制药公司)首席执行官,负责Unigene&8217;s债务的重大重组。债务人收购了Unigene几乎所有的资产后,Unigene于2013年7月申请破产。在创立Celimmune和CBV之前,帕尔默先生Vice President British Oxygen&8217;S Ohmeda Pharmaceutical Products,Inc.的业务开发,在该公司将其出售给百特国际有限公司领导的财团方面发挥了重要作用,他将该公司的吸入一氧化氮资产剥离为INO Therapeutics,Inc.(现为Ikaria/Mallinckrodt)。在他的领导下,作为创始总裁兼首席执行官,INO Therapeutics开发并商业化了世界上第一种选择性肺血管扩张剂Inomax&174;,建立了基于时间的定价,孤儿药专营权,随后于2015年被Mallinckrodt以23亿美元收购。在其职业生涯早期,Palmer先生在Reckitt Benckiser担任越来越重要的销售与市场营销领导职务。Palmer先生在布拉德福德大学(University of Bradford)获得工商管理硕士学位,并获得理学学士学位。the University of Manchester生物化学和应用分子生物学荣誉。
Ashleigh Palmer is a co-founder of Provention and has served as our President and Chief Executive Officer “CEO” and on the board of directors since inception in 2016. Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions, a role he has held from 2014 to 2020. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry. Since founding CBV in 2002 Mr. Palmer has advised numerous clients regarding corporate positioning and strategy, fund raising, merger and acquisition transactions, clinical development and commercialization, and has undertaken a number of CEO and board level transformational leadership and turnaround assignments for both public and private biopharma companies. From 2015 through 2017 Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing therapies for celiac disease and refractory celiac disease. Celimmune was acquired by Amgen Inc. in November 2017. Mr. Palmer served as Chief Executive Officer of Unigene Laboratories, Inc., a biopharmaceutical company, from 2010 to July 2013 in conjunction with a substantial restructuring of Unigene’s debt. Following the debtholder’s acquisition of substantially all of Unigene’s assets, Unigene filed for bankruptcy in July 2013. Prior to founding Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, establishing a time-based pricing, orphan drug franchise, subsequently acquired by Mallinckrodt in 2015 for $2.3 billion. Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Mr. Palmer received his MBA from the University of Bradford and his B.Sc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester.
Jeffrey Bluestone

Jeffrey Bluestone于2019年3月加入我们的董事会。Bluestone博士目前担任Sonoma Biotherapeutics的总裁兼首席执行官。他目前还担任加州大学旧金山分校(University of California San Francisco UCSF)的A.W.和Mary Margaret Clausen杰出教授。他此前曾于2015年6月至2019年12月担任帕克癌症免疫治疗研究所总裁兼首席执行官,并于2000年至2019年12月担任糖尿病中心激素研究所所长。从2010年到2015年,Bluestone博士担任UCSF的执行副校长兼教务长。Bluestone博士是免疫耐受网络的创始董事,该网络是NIH资助的最大的多中心临床免疫学研究计划,测试移植、自身免疫和哮喘/过敏中的新型免疫疗法。他被前Vice President乔·拜登(Joe Biden)任命为蓝丝带科学专家小组的成员,以指导国家癌症登月计划,并担任美国国家卫生研究院国家癌症研究所的高级研究员。Bluestone博士是一位成就卓越的科学研究人员,其近三十年的工作专注于了解在自身免疫,器官移植和癌症中控制T细胞激活和免疫耐受的基本过程。他的研究导致多种免疫疗法的开发和商业化,包括第一个FDA批准的靶向T细胞共刺激治疗自身免疫性疾病和器官移植的药物和第一个FDA批准的用于治疗转移性黑色素瘤的CTLA-4拮抗剂药物。Bluestone博士是一种新型抗CD3单克隆抗体(现称为Teplizumab)的早期开发人员团队的一员,这是一种促耐受性药物,在1型糖尿病T1D,银屑病关节炎和逆转肾移植排斥反应方面显示出临床活性。他在罗格斯大学(Rutgers University)获得学士学位和硕士学位,在威尔·康奈尔医学院(Weill Cornell Graduate School of Medical Science)获得免疫学博士学位。


Jeffrey Bluestone joined our board of directors in March 2019. Dr. Bluestone currently serves as the president and CEO of Sonoma Biotherapeutics, a role he has held since 2019. He has served as a member of the board of Gilead Sciences since 2019 and served on the board of Rheos Medicines in 2017. Dr. Bluestone has been the A.W. and Mary Margaret Clausen Distinguished Professor at University of California San Francisco UCSF in the Diabetes Center since 2000. From 2010 to 2015 Dr. Bluestone served as Executive Vice Chancellor and Provost at UCSF and from 2015 to 2019 as President and CEO of the Parker Institute for Cancer Immunotherapy. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter Exhibit A clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He was appointed by former Vice President, Joe Biden as a member of the Blue Ribbon Panel of scientific experts to guide the National Cancer Moonshot Initiative and also served as a senior investigator at the National Cancer Institute of the National Institutes of Health. Dr. Bluestone is a highly accomplished scientific researcher whose work over nearly three decades has focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved by the FDA for the treatment of metastatic melanoma. Dr. Bluestone was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes (T1D), psoriatic arthritis, and the reversal of kidney transplant rejection. He received his B.S. and M.S. from Rutgers University and his Ph.D. in immunology from the Weill Cornell Graduate School of Medical Science.
Jeffrey Bluestone于2019年3月加入我们的董事会。Bluestone博士目前担任Sonoma Biotherapeutics的总裁兼首席执行官。他目前还担任加州大学旧金山分校(University of California San Francisco UCSF)的A.W.和Mary Margaret Clausen杰出教授。他此前曾于2015年6月至2019年12月担任帕克癌症免疫治疗研究所总裁兼首席执行官,并于2000年至2019年12月担任糖尿病中心激素研究所所长。从2010年到2015年,Bluestone博士担任UCSF的执行副校长兼教务长。Bluestone博士是免疫耐受网络的创始董事,该网络是NIH资助的最大的多中心临床免疫学研究计划,测试移植、自身免疫和哮喘/过敏中的新型免疫疗法。他被前Vice President乔·拜登(Joe Biden)任命为蓝丝带科学专家小组的成员,以指导国家癌症登月计划,并担任美国国家卫生研究院国家癌症研究所的高级研究员。Bluestone博士是一位成就卓越的科学研究人员,其近三十年的工作专注于了解在自身免疫,器官移植和癌症中控制T细胞激活和免疫耐受的基本过程。他的研究导致多种免疫疗法的开发和商业化,包括第一个FDA批准的靶向T细胞共刺激治疗自身免疫性疾病和器官移植的药物和第一个FDA批准的用于治疗转移性黑色素瘤的CTLA-4拮抗剂药物。Bluestone博士是一种新型抗CD3单克隆抗体(现称为Teplizumab)的早期开发人员团队的一员,这是一种促耐受性药物,在1型糖尿病T1D,银屑病关节炎和逆转肾移植排斥反应方面显示出临床活性。他在罗格斯大学(Rutgers University)获得学士学位和硕士学位,在威尔·康奈尔医学院(Weill Cornell Graduate School of Medical Science)获得免疫学博士学位。
Jeffrey Bluestone joined our board of directors in March 2019. Dr. Bluestone currently serves as the president and CEO of Sonoma Biotherapeutics, a role he has held since 2019. He has served as a member of the board of Gilead Sciences since 2019 and served on the board of Rheos Medicines in 2017. Dr. Bluestone has been the A.W. and Mary Margaret Clausen Distinguished Professor at University of California San Francisco UCSF in the Diabetes Center since 2000. From 2010 to 2015 Dr. Bluestone served as Executive Vice Chancellor and Provost at UCSF and from 2015 to 2019 as President and CEO of the Parker Institute for Cancer Immunotherapy. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter Exhibit A clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He was appointed by former Vice President, Joe Biden as a member of the Blue Ribbon Panel of scientific experts to guide the National Cancer Moonshot Initiative and also served as a senior investigator at the National Cancer Institute of the National Institutes of Health. Dr. Bluestone is a highly accomplished scientific researcher whose work over nearly three decades has focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved by the FDA for the treatment of metastatic melanoma. Dr. Bluestone was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes (T1D), psoriatic arthritis, and the reversal of kidney transplant rejection. He received his B.S. and M.S. from Rutgers University and his Ph.D. in immunology from the Weill Cornell Graduate School of Medical Science.
Avery Catlin

Avery Catlin于2018年9月加入我们的董事会。他目前任职于Corbus Pharmaceutical Holdings,Inc.的董事会。Catlin先生曾担任CelldexTherapeutics,Inc.的高级副总裁和首席财务官,在那里他从股票、可转换债务和私募交易中筹集了5亿多美元,并设计和领导了成功完成几项资产收购的财务战略。在加入Celldex之前,Catlin先生曾在生物制药公司Endogen,Inc.和Repligen Corporation担任高级财务和运营职位。Catlin先生在弗吉尼亚大学(University of Virginia)获得心理学学士学位,在巴布森学院(Babson College)获得工商管理硕士学位。他也是一名注册会计师。


Avery Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc., a role he has held since August 2014. Mr. Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. from 2000 to 2017 where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions. Prior to Celldex, Mr. Catlin held senior financial and operational positions with public biopharma companies Endogen, Inc. and Repligen Corporation. Mr. Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College.
Avery Catlin于2018年9月加入我们的董事会。他目前任职于Corbus Pharmaceutical Holdings,Inc.的董事会。Catlin先生曾担任CelldexTherapeutics,Inc.的高级副总裁和首席财务官,在那里他从股票、可转换债务和私募交易中筹集了5亿多美元,并设计和领导了成功完成几项资产收购的财务战略。在加入Celldex之前,Catlin先生曾在生物制药公司Endogen,Inc.和Repligen Corporation担任高级财务和运营职位。Catlin先生在弗吉尼亚大学(University of Virginia)获得心理学学士学位,在巴布森学院(Babson College)获得工商管理硕士学位。他也是一名注册会计师。
Avery Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc., a role he has held since August 2014. Mr. Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. from 2000 to 2017 where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions. Prior to Celldex, Mr. Catlin held senior financial and operational positions with public biopharma companies Endogen, Inc. and Repligen Corporation. Mr. Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College.
Sean Doherty

Sean Doherty于2019年9月加入我们的董事会。Doherty先生是JDRF T1D基金(JDRF T1D Fund)的执行主席,该基金是一家1亿美元的风险慈善基金,使用尖端方法催化一型糖尿病的投资市场。他领导该基金的概念创建、设计和资本融资,自2016年成立以来,他一直推动其战略。他于2016年至2019年在JDRF国际董事会及其执行委员会任职。他从Bain Capital,LP(私人全球投资公司,他于2005年加入该公司,担任公司的第一总法律顾问)的董事总经理职务上退休。他曾担任Bain Capital公司的多种运营和选区管理职务,在那里他曾领导危机管理、新闻和对外沟通、政府关系、品牌和慈善倡议,并参与治理和资本筹集。职业生涯早期,他曾任职Ropes&Gray LLP,也曾担任波士顿联邦地区法官的法律职员。Doherty先生在哈佛法学院(Harvard Law School)以优异成绩获得法学博士学位,并在哈佛学院(Harvard College)以优异成绩获得政府学士学位。任职法学院之前,他曾担任美国海军中尉,在那里他曾任职中东部队护卫舰(the Middle East Force Frigate)(从1990年到1994年)。


Sean Doherty joined our board of directors in September 2019. He serves as the Chairman of the JDRF T1D Fund, a venture philanthropy fund accelerating life-changing solutions to cure type 1 diabetes through catalytic commercial investments, since its inception in 2016. Since 2019 Mr. Doherty has served on the board of directors of IM Therapeutics, Inc. From 2005 to 2018 Mr. Doherty was a Managing Director and the General Counsel of Bain Capital, L.P., a private global investment firm. Previously, he was an attorney at Ropes & Gray LLP and an officer in the United States Navy. Mr. Doherty received his B.A. degree in Government from Harvard College and J.D. from Harvard Law School.
Sean Doherty于2019年9月加入我们的董事会。Doherty先生是JDRF T1D基金(JDRF T1D Fund)的执行主席,该基金是一家1亿美元的风险慈善基金,使用尖端方法催化一型糖尿病的投资市场。他领导该基金的概念创建、设计和资本融资,自2016年成立以来,他一直推动其战略。他于2016年至2019年在JDRF国际董事会及其执行委员会任职。他从Bain Capital,LP(私人全球投资公司,他于2005年加入该公司,担任公司的第一总法律顾问)的董事总经理职务上退休。他曾担任Bain Capital公司的多种运营和选区管理职务,在那里他曾领导危机管理、新闻和对外沟通、政府关系、品牌和慈善倡议,并参与治理和资本筹集。职业生涯早期,他曾任职Ropes&Gray LLP,也曾担任波士顿联邦地区法官的法律职员。Doherty先生在哈佛法学院(Harvard Law School)以优异成绩获得法学博士学位,并在哈佛学院(Harvard College)以优异成绩获得政府学士学位。任职法学院之前,他曾担任美国海军中尉,在那里他曾任职中东部队护卫舰(the Middle East Force Frigate)(从1990年到1994年)。
Sean Doherty joined our board of directors in September 2019. He serves as the Chairman of the JDRF T1D Fund, a venture philanthropy fund accelerating life-changing solutions to cure type 1 diabetes through catalytic commercial investments, since its inception in 2016. Since 2019 Mr. Doherty has served on the board of directors of IM Therapeutics, Inc. From 2005 to 2018 Mr. Doherty was a Managing Director and the General Counsel of Bain Capital, L.P., a private global investment firm. Previously, he was an attorney at Ropes & Gray LLP and an officer in the United States Navy. Mr. Doherty received his B.A. degree in Government from Harvard College and J.D. from Harvard Law School.
John Jenkins

John Jenkins于2020年8月加入我们的董事会。从2002年到2017年,他担任美国食品和药物管理局(FDA)药物评估和研究中心(CDER)的新药办公室主任,负责1000多名机构员工和19个产品审查部门。在此期间,他负责审查数以千计的新药申请和生物许可申请,以及批准400多个新的分子实体。Jenkins博士曾担任CDER高级领导团队的成员,并参与广泛的政策举措,包括处方药使用费和生物仿制药计划的谈判和实施。Jenkins博士于1992年开始他的FDA职业生涯,担任肿瘤学和肺部药物产品部门的医疗官。1995年,他被任命为肺科药物产品部主任之前,他随后担任肺科医疗集团领导和代理部门主任。之后,他于1999年成为药物评估II办公室主任,并一直担任该职位,直到2002年被任命为OND的主任。他于2017年1月从FDA退休,在联邦服务超过25年后,他加入了Greenleaf Health,这是一家专注于FDA的战略咨询公司,在那里他担任药物和生物制品的负责人。Jenkins博士也是Corbus Pharmaceuticals的董事会成员,自2018年6月起在该公司任职。Jenkins博士是美国内科委员会颁发的内科和肺病方面的资格证书。他在田纳西大学孟菲斯分校获得医学学位,并在VA联邦大学/VA医学院完成了内科、肺病和重症监护医学的研究生医学培训。在加入FDA之前,Jenkins博士曾担任VCU/MCV的肺脏和危重护理医学助理教授,以及弗吉尼亚州里士满的Hunter Holmes McGuire医学中心的工作人员医师。


John Jenkins joined our board of directors in August 2020. Dr. Jenkins served as the Director of the Office of New Drugs OND at the United States Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017 where he was responsible for more than 1000 agency employees and 19 product-review divisions. During that time, he oversaw the review of thousands of new drug applications and biological licensing applications, as well as the approval of more than 400 new molecular entities. Dr. Jenkins served as a member of the CDER Senior Leadership Team and was involved in broad policy initiatives, including negotiation and implementation of the Prescription Drug User Fee and biosimilar programs. Dr. Jenkins began his FDA career in 1992 as a medical officer in the Division of Oncology and Pulmonary Drug Products. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the Division of Pulmonary Drug Products in 1995. He then became the Director of the Office of Drug Evaluation II in 1999 and remained in that position until he was appointed Director of OND in 2002. Following his retirement from the FDA after over 25 years of federal service in January 2017 Dr. Jenkins joined Greenleaf Health, an FDA-focused, strategic consulting firm where he served as Principal, Drug and Biological Products. Dr. Jenkins is also a member of the board of Corbus Pharmaceuticals, where he has served since June 2018. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his postgraduate medical training in internal medicine, pulmonary diseases, and critical care medicine at VA Commonwealth University/Medical College of VA. Prior to joining the FDA, Dr. Jenkins served as Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, VA.
John Jenkins于2020年8月加入我们的董事会。从2002年到2017年,他担任美国食品和药物管理局(FDA)药物评估和研究中心(CDER)的新药办公室主任,负责1000多名机构员工和19个产品审查部门。在此期间,他负责审查数以千计的新药申请和生物许可申请,以及批准400多个新的分子实体。Jenkins博士曾担任CDER高级领导团队的成员,并参与广泛的政策举措,包括处方药使用费和生物仿制药计划的谈判和实施。Jenkins博士于1992年开始他的FDA职业生涯,担任肿瘤学和肺部药物产品部门的医疗官。1995年,他被任命为肺科药物产品部主任之前,他随后担任肺科医疗集团领导和代理部门主任。之后,他于1999年成为药物评估II办公室主任,并一直担任该职位,直到2002年被任命为OND的主任。他于2017年1月从FDA退休,在联邦服务超过25年后,他加入了Greenleaf Health,这是一家专注于FDA的战略咨询公司,在那里他担任药物和生物制品的负责人。Jenkins博士也是Corbus Pharmaceuticals的董事会成员,自2018年6月起在该公司任职。Jenkins博士是美国内科委员会颁发的内科和肺病方面的资格证书。他在田纳西大学孟菲斯分校获得医学学位,并在VA联邦大学/VA医学院完成了内科、肺病和重症监护医学的研究生医学培训。在加入FDA之前,Jenkins博士曾担任VCU/MCV的肺脏和危重护理医学助理教授,以及弗吉尼亚州里士满的Hunter Holmes McGuire医学中心的工作人员医师。
John Jenkins joined our board of directors in August 2020. Dr. Jenkins served as the Director of the Office of New Drugs OND at the United States Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017 where he was responsible for more than 1000 agency employees and 19 product-review divisions. During that time, he oversaw the review of thousands of new drug applications and biological licensing applications, as well as the approval of more than 400 new molecular entities. Dr. Jenkins served as a member of the CDER Senior Leadership Team and was involved in broad policy initiatives, including negotiation and implementation of the Prescription Drug User Fee and biosimilar programs. Dr. Jenkins began his FDA career in 1992 as a medical officer in the Division of Oncology and Pulmonary Drug Products. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the Division of Pulmonary Drug Products in 1995. He then became the Director of the Office of Drug Evaluation II in 1999 and remained in that position until he was appointed Director of OND in 2002. Following his retirement from the FDA after over 25 years of federal service in January 2017 Dr. Jenkins joined Greenleaf Health, an FDA-focused, strategic consulting firm where he served as Principal, Drug and Biological Products. Dr. Jenkins is also a member of the board of Corbus Pharmaceuticals, where he has served since June 2018. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his postgraduate medical training in internal medicine, pulmonary diseases, and critical care medicine at VA Commonwealth University/Medical College of VA. Prior to joining the FDA, Dr. Jenkins served as Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, VA.
Wayne Pisano

Wayne Pisano, 他拥有工商管理硕士学位。他拥有超过30年的制药行业高管的任职经验,并被世界疫苗大会(World Vaccine Congress)评为2010年的年度制药公司执行官。他目前担任VaxInnate公司(一个私营生物技术公司)的总裁兼首席执行官。他是Sanofi Pasteur公司(世界上最大的疫苗公司之一)的前任总裁兼首席执行官。加入Sanofi Pasteur公司之前,他曾任职Novartis公司(原名Sandoz公司)11年。他持有圣约翰费舍尔大学(Saint John Fisher College)(位于纽约)的生物学学士学位,以及俄亥俄州代顿大学(University of Dayton, Ohio)的工商管理硕士学位。


Wayne Pisano,has served as a member of Altimmune, Inc. Board of Directors since August 2018. Mr. Pisano also has served on the board of directors of Oncolytics Biotech Inc. (Nasdaq: ONCY), a biotechnology company, since May 2013. Mr. Pisano served on the board of directors of Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company, from April 2018 until April 2023 when it was acquired by Sanofi, and IMV INC. (Nasdaq: IMV) a bio pharmaceutical company from October 2011 until March 2021. Mr. Pisano served as president and Chief Executive Officer of VaxInnate Corporation, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and Chief Executive Officer in 2007, the position he successfully held until his retirement in 2011. He has a Bachelor of Science in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.
Wayne Pisano, 他拥有工商管理硕士学位。他拥有超过30年的制药行业高管的任职经验,并被世界疫苗大会(World Vaccine Congress)评为2010年的年度制药公司执行官。他目前担任VaxInnate公司(一个私营生物技术公司)的总裁兼首席执行官。他是Sanofi Pasteur公司(世界上最大的疫苗公司之一)的前任总裁兼首席执行官。加入Sanofi Pasteur公司之前,他曾任职Novartis公司(原名Sandoz公司)11年。他持有圣约翰费舍尔大学(Saint John Fisher College)(位于纽约)的生物学学士学位,以及俄亥俄州代顿大学(University of Dayton, Ohio)的工商管理硕士学位。
Wayne Pisano,has served as a member of Altimmune, Inc. Board of Directors since August 2018. Mr. Pisano also has served on the board of directors of Oncolytics Biotech Inc. (Nasdaq: ONCY), a biotechnology company, since May 2013. Mr. Pisano served on the board of directors of Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company, from April 2018 until April 2023 when it was acquired by Sanofi, and IMV INC. (Nasdaq: IMV) a bio pharmaceutical company from October 2011 until March 2021. Mr. Pisano served as president and Chief Executive Officer of VaxInnate Corporation, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and Chief Executive Officer in 2007, the position he successfully held until his retirement in 2011. He has a Bachelor of Science in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.
Nancy Wysenski

Nancy Wysenski,2014年3月起,她担任我公司董事会成员。2009年12月至2012年6月,她担任上市制药公司Vertex Pharmaceuticals Incorporated的执行副总裁和首席商务官。加入Vertex之前,她担任Endo Pharmaceuticals的首席运营官,该公司是有1200员工的专业制药公司,她领导销售、营销、商业运营、供应链管理、人力资源和多个商业发展领域。加入Endo之前,她参与了EMD Pharmaceuticals, Inc.的创立,担任多个领导职位,包括2001至2006年担任总裁和首席执行官,1999至2001年担任商务副总裁。1984至1998年,她在大型制药公司担任销售职位,包括Astra Merck, Inc.的现场销售副总裁。她是上市生物制药公司Alkermes plc的董事和私人公司Reata Pharmaceuticals, Inc.的董事。她是医疗保健商业女性协会研究三角园分会(Research Triangle Park Chapter of the Healthcare Businesswomen’s Association)的创始人,并担任医疗保健商业女性协会提名委员会和全国咨询委员会成员。她在肯特州立大学(Kent State University)获得护理学士学位,在鲍德温·华莱士学院(Baldwin-Wallace College)获得工商管理学硕士学位。


Nancy Wysenski joined our board of directors in May 2020. She served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski has served as a member of the board of directors of Alkermes plc and Cytokinetics Inc. since 2013 and 2020 respectively. Ms. Wysenski formerly served as a director on the board of Tetraphase Pharmaceuticals Inc. from 2014 to 2020 Dova Pharmaceuticals, Inc. from 2018 to 2019 and Inovio Pharmaceuticals, Inc. from 2015 to 2017. She is a founder of the Research Triangle Park chapter of the Healthcare Businesswomen's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association.
Nancy Wysenski,2014年3月起,她担任我公司董事会成员。2009年12月至2012年6月,她担任上市制药公司Vertex Pharmaceuticals Incorporated的执行副总裁和首席商务官。加入Vertex之前,她担任Endo Pharmaceuticals的首席运营官,该公司是有1200员工的专业制药公司,她领导销售、营销、商业运营、供应链管理、人力资源和多个商业发展领域。加入Endo之前,她参与了EMD Pharmaceuticals, Inc.的创立,担任多个领导职位,包括2001至2006年担任总裁和首席执行官,1999至2001年担任商务副总裁。1984至1998年,她在大型制药公司担任销售职位,包括Astra Merck, Inc.的现场销售副总裁。她是上市生物制药公司Alkermes plc的董事和私人公司Reata Pharmaceuticals, Inc.的董事。她是医疗保健商业女性协会研究三角园分会(Research Triangle Park Chapter of the Healthcare Businesswomen’s Association)的创始人,并担任医疗保健商业女性协会提名委员会和全国咨询委员会成员。她在肯特州立大学(Kent State University)获得护理学士学位,在鲍德温·华莱士学院(Baldwin-Wallace College)获得工商管理学硕士学位。
Nancy Wysenski joined our board of directors in May 2020. She served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski has served as a member of the board of directors of Alkermes plc and Cytokinetics Inc. since 2013 and 2020 respectively. Ms. Wysenski formerly served as a director on the board of Tetraphase Pharmaceuticals Inc. from 2014 to 2020 Dova Pharmaceuticals, Inc. from 2018 to 2019 and Inovio Pharmaceuticals, Inc. from 2015 to 2017. She is a founder of the Research Triangle Park chapter of the Healthcare Businesswomen's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association.

高管简历

中英对照 |  中文 |  英文
Ashleigh Palmer

Ashleigh Palmer是ProVention的联合创始人,自2016年成立以来一直担任我们的总裁兼首席执行官,并担任董事会成员。Palmer先生目前担任Third Pole的董事会非执行董事,该公司是一家临床阶段的生物制药公司,为某些危及生命和使人衰弱的重症监护和慢性心肺疾病开发电动产生的吸入一氧化氮。Palmer先生也是Creative BioVentures™;Corp.的总裁。CBV,一家服务于生物制药行业的战略咨询公司。自2002年创立CBV以来,Palmer先生为众多客户提供企业定位和战略,资金筹集,并购交易,临床开发和商业化方面的建议,并为公共和私人生物制药公司承担了许多首席执行官和董事会级别的转型领导和周转任务。2015年至2017年,Palmer先生担任Celimmune,LLC(一家临床开发阶段的免疫疗法公司,致力于开发腹腔疾病和难治性腹腔疾病的疗法)的执行主席。Celimmune于2017年11月被安进公司收购。Palmer从2010年到2013年7月担任Unigene Laboratories,Inc.(一家生物制药公司)首席执行官,负责Unigene&8217;s债务的重大重组。债务人收购了Unigene几乎所有的资产后,Unigene于2013年7月申请破产。在创立Celimmune和CBV之前,帕尔默先生Vice President British Oxygen&8217;S Ohmeda Pharmaceutical Products,Inc.的业务开发,在该公司将其出售给百特国际有限公司领导的财团方面发挥了重要作用,他将该公司的吸入一氧化氮资产剥离为INO Therapeutics,Inc.(现为Ikaria/Mallinckrodt)。在他的领导下,作为创始总裁兼首席执行官,INO Therapeutics开发并商业化了世界上第一种选择性肺血管扩张剂Inomax&174;,建立了基于时间的定价,孤儿药专营权,随后于2015年被Mallinckrodt以23亿美元收购。在其职业生涯早期,Palmer先生在Reckitt Benckiser担任越来越重要的销售与市场营销领导职务。Palmer先生在布拉德福德大学(University of Bradford)获得工商管理硕士学位,并获得理学学士学位。the University of Manchester生物化学和应用分子生物学荣誉。


Ashleigh Palmer is a co-founder of Provention and has served as our President and Chief Executive Officer “CEO” and on the board of directors since inception in 2016. Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions, a role he has held from 2014 to 2020. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry. Since founding CBV in 2002 Mr. Palmer has advised numerous clients regarding corporate positioning and strategy, fund raising, merger and acquisition transactions, clinical development and commercialization, and has undertaken a number of CEO and board level transformational leadership and turnaround assignments for both public and private biopharma companies. From 2015 through 2017 Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing therapies for celiac disease and refractory celiac disease. Celimmune was acquired by Amgen Inc. in November 2017. Mr. Palmer served as Chief Executive Officer of Unigene Laboratories, Inc., a biopharmaceutical company, from 2010 to July 2013 in conjunction with a substantial restructuring of Unigene’s debt. Following the debtholder’s acquisition of substantially all of Unigene’s assets, Unigene filed for bankruptcy in July 2013. Prior to founding Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, establishing a time-based pricing, orphan drug franchise, subsequently acquired by Mallinckrodt in 2015 for $2.3 billion. Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Mr. Palmer received his MBA from the University of Bradford and his B.Sc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester.
Ashleigh Palmer是ProVention的联合创始人,自2016年成立以来一直担任我们的总裁兼首席执行官,并担任董事会成员。Palmer先生目前担任Third Pole的董事会非执行董事,该公司是一家临床阶段的生物制药公司,为某些危及生命和使人衰弱的重症监护和慢性心肺疾病开发电动产生的吸入一氧化氮。Palmer先生也是Creative BioVentures™;Corp.的总裁。CBV,一家服务于生物制药行业的战略咨询公司。自2002年创立CBV以来,Palmer先生为众多客户提供企业定位和战略,资金筹集,并购交易,临床开发和商业化方面的建议,并为公共和私人生物制药公司承担了许多首席执行官和董事会级别的转型领导和周转任务。2015年至2017年,Palmer先生担任Celimmune,LLC(一家临床开发阶段的免疫疗法公司,致力于开发腹腔疾病和难治性腹腔疾病的疗法)的执行主席。Celimmune于2017年11月被安进公司收购。Palmer从2010年到2013年7月担任Unigene Laboratories,Inc.(一家生物制药公司)首席执行官,负责Unigene&8217;s债务的重大重组。债务人收购了Unigene几乎所有的资产后,Unigene于2013年7月申请破产。在创立Celimmune和CBV之前,帕尔默先生Vice President British Oxygen&8217;S Ohmeda Pharmaceutical Products,Inc.的业务开发,在该公司将其出售给百特国际有限公司领导的财团方面发挥了重要作用,他将该公司的吸入一氧化氮资产剥离为INO Therapeutics,Inc.(现为Ikaria/Mallinckrodt)。在他的领导下,作为创始总裁兼首席执行官,INO Therapeutics开发并商业化了世界上第一种选择性肺血管扩张剂Inomax&174;,建立了基于时间的定价,孤儿药专营权,随后于2015年被Mallinckrodt以23亿美元收购。在其职业生涯早期,Palmer先生在Reckitt Benckiser担任越来越重要的销售与市场营销领导职务。Palmer先生在布拉德福德大学(University of Bradford)获得工商管理硕士学位,并获得理学学士学位。the University of Manchester生物化学和应用分子生物学荣誉。
Ashleigh Palmer is a co-founder of Provention and has served as our President and Chief Executive Officer “CEO” and on the board of directors since inception in 2016. Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions, a role he has held from 2014 to 2020. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry. Since founding CBV in 2002 Mr. Palmer has advised numerous clients regarding corporate positioning and strategy, fund raising, merger and acquisition transactions, clinical development and commercialization, and has undertaken a number of CEO and board level transformational leadership and turnaround assignments for both public and private biopharma companies. From 2015 through 2017 Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing therapies for celiac disease and refractory celiac disease. Celimmune was acquired by Amgen Inc. in November 2017. Mr. Palmer served as Chief Executive Officer of Unigene Laboratories, Inc., a biopharmaceutical company, from 2010 to July 2013 in conjunction with a substantial restructuring of Unigene’s debt. Following the debtholder’s acquisition of substantially all of Unigene’s assets, Unigene filed for bankruptcy in July 2013. Prior to founding Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, establishing a time-based pricing, orphan drug franchise, subsequently acquired by Mallinckrodt in 2015 for $2.3 billion. Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Mr. Palmer received his MBA from the University of Bradford and his B.Sc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester.
Andrew Drechsler

Andrew Drechsler自2020年8月起担任董事。Drechsler先生自2017年9月起担任ProVention Bio(一家上市生物制药公司,致力于拦截和预防免疫介导的疾病)的首席财务官。从2012年到2017年3月,德雷克斯勒先生担任Insmed Incorporated的首席财务官,该公司是一家上市的生物制药公司,致力于改善孤儿肺病患者的生活。在此之前,Drechsler先生是Vaxinnate公司的首席财务官,该公司是新泽西州克兰伯里的一家私营生物技术公司。Drechsler从2005年到2007年担任Valera Pharmaceuticals,Inc.首席财务官,帮助Valera通过首次公开募股筹集资金。Drechsler先生在维拉诺瓦大学(Villanova University)获得会计学学士学位,以优异成绩毕业。他在新泽西州获得了他的注册会计师执照,并通过青少年糖尿病研究基金会积极为青少年糖尿病筹集资金和提高认识。


Andrew Drechsler,has served as director since August 2020. Mr. Drechsler has also served as a Senior Finance Executive at BioDrex since April 2017. From September 2017 to December 2021, Mr. Drechsler served as Chief Financial Officer of Provention Bio, a publicly-traded biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases. From 2012 to March 2017, Mr. Drechsler was the Chief Financial Officer at Insmed Incorporated, a publicly-traded biopharmaceutical company dedicated to improving the lives of patients with orphan pulmonary diseases. Prior to that, Mr. Drechsler was Chief Financial Officer at VaxInnate, a privately held biotechnology company, and Chief Financial Officer for Valera Pharmaceuticals, Inc. Mr. Drechsler received a B.S. in Accountancy from Villanova University, graduating Magna Cum Laude. He obtained his Certified Public Accountant license in the State of New Jersey and actively raises funds for and awareness of type one diabetes via the Juvenile Diabetes Research Foundation.
Andrew Drechsler自2020年8月起担任董事。Drechsler先生自2017年9月起担任ProVention Bio(一家上市生物制药公司,致力于拦截和预防免疫介导的疾病)的首席财务官。从2012年到2017年3月,德雷克斯勒先生担任Insmed Incorporated的首席财务官,该公司是一家上市的生物制药公司,致力于改善孤儿肺病患者的生活。在此之前,Drechsler先生是Vaxinnate公司的首席财务官,该公司是新泽西州克兰伯里的一家私营生物技术公司。Drechsler从2005年到2007年担任Valera Pharmaceuticals,Inc.首席财务官,帮助Valera通过首次公开募股筹集资金。Drechsler先生在维拉诺瓦大学(Villanova University)获得会计学学士学位,以优异成绩毕业。他在新泽西州获得了他的注册会计师执照,并通过青少年糖尿病研究基金会积极为青少年糖尿病筹集资金和提高认识。
Andrew Drechsler,has served as director since August 2020. Mr. Drechsler has also served as a Senior Finance Executive at BioDrex since April 2017. From September 2017 to December 2021, Mr. Drechsler served as Chief Financial Officer of Provention Bio, a publicly-traded biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases. From 2012 to March 2017, Mr. Drechsler was the Chief Financial Officer at Insmed Incorporated, a publicly-traded biopharmaceutical company dedicated to improving the lives of patients with orphan pulmonary diseases. Prior to that, Mr. Drechsler was Chief Financial Officer at VaxInnate, a privately held biotechnology company, and Chief Financial Officer for Valera Pharmaceuticals, Inc. Mr. Drechsler received a B.S. in Accountancy from Villanova University, graduating Magna Cum Laude. He obtained his Certified Public Accountant license in the State of New Jersey and actively raises funds for and awareness of type one diabetes via the Juvenile Diabetes Research Foundation.
Francisco Leon

ProVention的联合创始人兼首席科学官Francisco Leon于2017年10月加入ProVention。Leon博士最近担任Celimmune,LLC的首席执行官兼首席医疗官,该公司是一家临床开发阶段的免疫治疗公司,致力于开发针对腹腔疾病和难治性腹腔疾病肠道淋巴瘤的转化疗法。Celimmune于2017年11月被安进公司收购。在2015年创立Celimmune之前,Leon博士曾担任强生公司Janssen Pharmaceuticals的Vice President兼转化医学主管,在那里他领导了免疫学的早期临床开发。在2010年加入Janssen之前,Leon博士曾担任Alba Therapeutics的首席医疗官,MedImmune AstraZeneca的临床开发,炎症和呼吸总监,Bristol-Myers Squibb的临床发现,免疫学和肿瘤学总监。在加入生物制药行业之前,Leon博士担任美国国立卫生研究院(NIH)过敏和传染病研究所(NIAID)的博士后研究员。2011年他成为费城杰斐逊医学院(Jefferson Medical College)的医学副教授,在那里他继续为消化内科的临床研究努力做出贡献。Leon博士是一名临床和转化免疫学家,在西班牙马德里Aut Noma University获得医学博士学位和博士学位,在西班牙马德里Ramon y Cajal Hospital获得临床免疫学专业学位。他是the American Gastroenterology Association的研究员。


Francisco Leon co-founder of Provention and its Chief Scientific Officer "CSO", joined Provention in October 2017. Dr. Leon was most recently the Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing transformational therapies for celiac disease and refractory celiac disease (intestinal lymphoma) from 2015 to 2017. Celimmune was acquired by Amgen Inc. in November 2017. Additionally, Dr. Leon is a co-founder and shareholder of Glutenostics, Inc. since April 2016. Prior to founding Celimmune in 2015 Dr. Leon served as Vice President and Head of Translational Medicine at Johnson & Johnson's Janssen Pharmaceuticals, where he led early-stage clinical development in immunology. Before joining Janssen in 2010 Dr. Leon served as Chief Medical Officer at Alba Therapeutics; Director of Clinical Development, Inflammation & Respiratory at Medimmune (AstraZeneca); and Director of Clinical Discovery, Immunology & Oncology at Bristol-Myers Squibb. Prior to joining the biopharma industry, Dr. Leon served as a Postdoctoral Fellow at the National Institutes for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In 2011 he became an Associate Professor of Medicine at Jefferson Medical College in Philadelphia, where he continues to contribute to the clinical research efforts of the Department of Gastroenterology. Dr. Leon is a clinical and translational immunologist who received his M.D. and Ph.D. from Autónoma University in Madrid, Spain.
ProVention的联合创始人兼首席科学官Francisco Leon于2017年10月加入ProVention。Leon博士最近担任Celimmune,LLC的首席执行官兼首席医疗官,该公司是一家临床开发阶段的免疫治疗公司,致力于开发针对腹腔疾病和难治性腹腔疾病肠道淋巴瘤的转化疗法。Celimmune于2017年11月被安进公司收购。在2015年创立Celimmune之前,Leon博士曾担任强生公司Janssen Pharmaceuticals的Vice President兼转化医学主管,在那里他领导了免疫学的早期临床开发。在2010年加入Janssen之前,Leon博士曾担任Alba Therapeutics的首席医疗官,MedImmune AstraZeneca的临床开发,炎症和呼吸总监,Bristol-Myers Squibb的临床发现,免疫学和肿瘤学总监。在加入生物制药行业之前,Leon博士担任美国国立卫生研究院(NIH)过敏和传染病研究所(NIAID)的博士后研究员。2011年他成为费城杰斐逊医学院(Jefferson Medical College)的医学副教授,在那里他继续为消化内科的临床研究努力做出贡献。Leon博士是一名临床和转化免疫学家,在西班牙马德里Aut Noma University获得医学博士学位和博士学位,在西班牙马德里Ramon y Cajal Hospital获得临床免疫学专业学位。他是the American Gastroenterology Association的研究员。
Francisco Leon co-founder of Provention and its Chief Scientific Officer "CSO", joined Provention in October 2017. Dr. Leon was most recently the Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing transformational therapies for celiac disease and refractory celiac disease (intestinal lymphoma) from 2015 to 2017. Celimmune was acquired by Amgen Inc. in November 2017. Additionally, Dr. Leon is a co-founder and shareholder of Glutenostics, Inc. since April 2016. Prior to founding Celimmune in 2015 Dr. Leon served as Vice President and Head of Translational Medicine at Johnson & Johnson's Janssen Pharmaceuticals, where he led early-stage clinical development in immunology. Before joining Janssen in 2010 Dr. Leon served as Chief Medical Officer at Alba Therapeutics; Director of Clinical Development, Inflammation & Respiratory at Medimmune (AstraZeneca); and Director of Clinical Discovery, Immunology & Oncology at Bristol-Myers Squibb. Prior to joining the biopharma industry, Dr. Leon served as a Postdoctoral Fellow at the National Institutes for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In 2011 he became an Associate Professor of Medicine at Jefferson Medical College in Philadelphia, where he continues to contribute to the clinical research efforts of the Department of Gastroenterology. Dr. Leon is a clinical and translational immunologist who received his M.D. and Ph.D. from Autónoma University in Madrid, Spain.
Eleanor Ramos

Eleanor Ramos于2017年7月加入ProVention,担任首席医疗官。Ramos博士的背景包括在自身免疫,炎症,器官移植排斥反应以及治疗急性和慢性病毒感染方面的重要临床专业知识。在加入ProVention之前,Ramos博士于2014年至2016年担任Global Blood Therapeutics Inc.的首席医疗官,该公司是一家生物制药公司,致力于开发新型疗法来治疗基于血液和低氧性肺病。她过去的经验包括担任Theraclone Sciences(治疗性抗体发现和开发公司)的首席医疗官,在那里她从2011年到2014年监督包括严重流感在内的病毒性疾病的临床计划的开发,并担任ZymoGenetics,Inc.的首席医疗官。从2009年到2011年监督其在传染病/丙肝,免疫学/狼疮性肾炎,肿瘤学和止血方面的临床组合。Ramos博士目前是EpiVax Oncology的科学顾问委员会成员,该公司是一家专注于开发个性化癌症疫苗的私营生物技术公司,也是ASK的董事会成员,ASK是一家非营利组织,致力于提高女性对肺癌的认识,尤其是那些亚裔。她的经验还包括在免疫耐受网络领导临床试验小组,该网络是由国家过敏和传染病研究所资助的临床研究合作网络。她持有Tufts University的医学学位和本科学位,以及哈佛医学院Brigham and Women&8217;s Hospital肾脏学子专业的高级培训,专注于移植免疫学。


Eleanor Ramos joined Provention in July 2017 as its Chief Medical Officer “CMO”. Dr. Ramos’ background includes significant clinical expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections. Prior to joining Provention, Dr. Ramos served as a Chief Medical Officer of Global Blood Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapeutics to treat blood-based and hypoxemic pulmonary disorders from 2014 to 2016. Her past experience includes roles as Chief Medical Officer of Theraclone Sciences, a therapeutic antibody discovery and development company, where she oversaw the development of clinical programs in viral diseases including severe influenza from 2011 to 2014 and as Chief Medical Officer at ZymoGenetics, Inc., overseeing its clinical portfolio across infectious diseases/hepatitis C, immunology/lupus nephritis, oncology and hemostasis from 2009 to 2011. Dr. Ramos is currently a member of the Scientific Advisory Board of EpiVax Oncology, a private biotechnology company focused on developing personalized cancer vaccines. Her experience also encompasses leading the Clinical Trials Group at the Immune Tolerance Network, a collaborative network for clinical research funded by the National Institute of Allergy and Infectious Diseases. She holds a medical degree and undergraduate degree from Tufts University, along with advanced training in the subspecialty of nephrology with a focus on transplantation immunology at Brigham and Women’s Hospital, Harvard Medical School.
Eleanor Ramos于2017年7月加入ProVention,担任首席医疗官。Ramos博士的背景包括在自身免疫,炎症,器官移植排斥反应以及治疗急性和慢性病毒感染方面的重要临床专业知识。在加入ProVention之前,Ramos博士于2014年至2016年担任Global Blood Therapeutics Inc.的首席医疗官,该公司是一家生物制药公司,致力于开发新型疗法来治疗基于血液和低氧性肺病。她过去的经验包括担任Theraclone Sciences(治疗性抗体发现和开发公司)的首席医疗官,在那里她从2011年到2014年监督包括严重流感在内的病毒性疾病的临床计划的开发,并担任ZymoGenetics,Inc.的首席医疗官。从2009年到2011年监督其在传染病/丙肝,免疫学/狼疮性肾炎,肿瘤学和止血方面的临床组合。Ramos博士目前是EpiVax Oncology的科学顾问委员会成员,该公司是一家专注于开发个性化癌症疫苗的私营生物技术公司,也是ASK的董事会成员,ASK是一家非营利组织,致力于提高女性对肺癌的认识,尤其是那些亚裔。她的经验还包括在免疫耐受网络领导临床试验小组,该网络是由国家过敏和传染病研究所资助的临床研究合作网络。她持有Tufts University的医学学位和本科学位,以及哈佛医学院Brigham and Women&8217;s Hospital肾脏学子专业的高级培训,专注于移植免疫学。
Eleanor Ramos joined Provention in July 2017 as its Chief Medical Officer “CMO”. Dr. Ramos’ background includes significant clinical expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections. Prior to joining Provention, Dr. Ramos served as a Chief Medical Officer of Global Blood Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapeutics to treat blood-based and hypoxemic pulmonary disorders from 2014 to 2016. Her past experience includes roles as Chief Medical Officer of Theraclone Sciences, a therapeutic antibody discovery and development company, where she oversaw the development of clinical programs in viral diseases including severe influenza from 2011 to 2014 and as Chief Medical Officer at ZymoGenetics, Inc., overseeing its clinical portfolio across infectious diseases/hepatitis C, immunology/lupus nephritis, oncology and hemostasis from 2009 to 2011. Dr. Ramos is currently a member of the Scientific Advisory Board of EpiVax Oncology, a private biotechnology company focused on developing personalized cancer vaccines. Her experience also encompasses leading the Clinical Trials Group at the Immune Tolerance Network, a collaborative network for clinical research funded by the National Institute of Allergy and Infectious Diseases. She holds a medical degree and undergraduate degree from Tufts University, along with advanced training in the subspecialty of nephrology with a focus on transplantation immunology at Brigham and Women’s Hospital, Harvard Medical School.
Jason Hoitt

Jason Hoitt于2020年1月加入ProVention担任首席商务官。在加入ProVention之前,Hoitt先生于2018年12月至2019年12月担任Dova Pharmaceuticals的首席商务官,该公司被瑞典孤儿Biovitrum AB收购,他在该公司领导了所有商业活动,包括针对慢性免疫血小板减少症的Doptelet®;Avatrombopag的上市前和上市战略以及执行。在加入Dova Pharmaceuticals之前,Hoitt先生于2017年5月至2018年12月担任Insmed Incorporated Vice President兼销售主管。从2013年到2017年5月,Hoitt先生在Sarepta Therapeutics担任医疗事务和美国销售方面的各种领导职务。Hoitt从2010年到2013年在Vertex Pharmaceuticals担任市场营销与销售高级职位。Hoitt从2004年到2010年在Gilead Sciences担任多个职位。Hoitt先生于1999年在波士顿塔夫茨医学院新英格兰医学中心(Boston’;s New England Medical Center,Tufts Medical School)开始他的职业生涯,这导致他在阿斯利康(AstraZeneca)和先灵葆雅肿瘤生物技术公司(Schering Oncology-Biotech)担任生物制药角色。Hoitt先生拥有马萨诸塞州伍斯特的圣十字学院(College of the Holy Cross)的西班牙语学士学位。


Jason Hoitt joined Provention as its Chief Commercial Officer “CCO” in January 2020. Prior to joining Provention, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals (acquired by Swedish Orphan Biovitrum AB, or Sobi) and led all commercial efforts including the pre-launch and launch strategy and execution for DOPTELET ® (avatrombopag) targeting chronic immune thrombocytopenia. Prior to Dova Pharmacetucials, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales for the launch of Arikayce. Mr. Hoitt was also a member of the commercial leadership team at Sarepta Therapeutics, where he launched Exondys 51. Prior to Sarepta he held roles of increasing responsibility at Vertex Pharmaceuticals, where he launched Incivek, and Gilead Sciences, working on Hepsera and the launch of Viread HBV. Mr. Hoitt holds a B.A. from the College of the Holy Cross.
Jason Hoitt于2020年1月加入ProVention担任首席商务官。在加入ProVention之前,Hoitt先生于2018年12月至2019年12月担任Dova Pharmaceuticals的首席商务官,该公司被瑞典孤儿Biovitrum AB收购,他在该公司领导了所有商业活动,包括针对慢性免疫血小板减少症的Doptelet®;Avatrombopag的上市前和上市战略以及执行。在加入Dova Pharmaceuticals之前,Hoitt先生于2017年5月至2018年12月担任Insmed Incorporated Vice President兼销售主管。从2013年到2017年5月,Hoitt先生在Sarepta Therapeutics担任医疗事务和美国销售方面的各种领导职务。Hoitt从2010年到2013年在Vertex Pharmaceuticals担任市场营销与销售高级职位。Hoitt从2004年到2010年在Gilead Sciences担任多个职位。Hoitt先生于1999年在波士顿塔夫茨医学院新英格兰医学中心(Boston’;s New England Medical Center,Tufts Medical School)开始他的职业生涯,这导致他在阿斯利康(AstraZeneca)和先灵葆雅肿瘤生物技术公司(Schering Oncology-Biotech)担任生物制药角色。Hoitt先生拥有马萨诸塞州伍斯特的圣十字学院(College of the Holy Cross)的西班牙语学士学位。
Jason Hoitt joined Provention as its Chief Commercial Officer “CCO” in January 2020. Prior to joining Provention, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals (acquired by Swedish Orphan Biovitrum AB, or Sobi) and led all commercial efforts including the pre-launch and launch strategy and execution for DOPTELET ® (avatrombopag) targeting chronic immune thrombocytopenia. Prior to Dova Pharmacetucials, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales for the launch of Arikayce. Mr. Hoitt was also a member of the commercial leadership team at Sarepta Therapeutics, where he launched Exondys 51. Prior to Sarepta he held roles of increasing responsibility at Vertex Pharmaceuticals, where he launched Incivek, and Gilead Sciences, working on Hepsera and the launch of Viread HBV. Mr. Hoitt holds a B.A. from the College of the Holy Cross.
Heidy King Jones

Heidy King Jones于2020年8月加入Provention担任首席法务官。她在生物技术和制药行业拥有近13年的公司法律顾问和律师事务所经验。作为首席法务官,King-Jones女士支持Provention Bio公司坚持合规、公司治理、法律和企业风险管理最佳实践的承诺。在加入Provention之前,她曾担任Axcella Health,Inc.的高级副总裁and General Counsel(从2018年1月到2020年8月)。在加入Axcella之前,她从2013年7月到2018年1月在Sarepta Therapeutics担任越来越多的法律职务,包括公司法律部主管和Exondys51商业化的首席律师。King-Jones女士的职业生涯始于担任Ropes&Gray LLP’;S Securities&Public Company Practice Group的一员。她拥有达特茅斯学院(Dartmouth College)的学士学位和法学博士学位。来自康奈尔大学法学院。


Heidy King Jones joined Provention as its Chief Legal Officer "CLO" in August 2020. As Chief Legal Officer, Ms. King-Jones supports Provention Bio's commitment to upholding the best practices of compliance, corporate governance, and legal and enterprise risk management. Prior to joining Provention, Ms. King-Jones served as Senior Vice President and General Counsel of Axcella Health, Inc. where she worked from January 2018 to August 2020. Prior to Axcella, she held legal roles of increasing responsibility at Sarepta Therapeutics from July 2013 to January 2018 including head of Corporate Law Department and lead attorney for commercialization of Exondys 51. Ms. King-Jones started her career as a part of Ropes & Gray LLP's Securities & Public Company Practice Group. She holds a B.A. from Dartmouth College and a J.D. and LL.M. from Cornell Law School.
Heidy King Jones于2020年8月加入Provention担任首席法务官。她在生物技术和制药行业拥有近13年的公司法律顾问和律师事务所经验。作为首席法务官,King-Jones女士支持Provention Bio公司坚持合规、公司治理、法律和企业风险管理最佳实践的承诺。在加入Provention之前,她曾担任Axcella Health,Inc.的高级副总裁and General Counsel(从2018年1月到2020年8月)。在加入Axcella之前,她从2013年7月到2018年1月在Sarepta Therapeutics担任越来越多的法律职务,包括公司法律部主管和Exondys51商业化的首席律师。King-Jones女士的职业生涯始于担任Ropes&Gray LLP’;S Securities&Public Company Practice Group的一员。她拥有达特茅斯学院(Dartmouth College)的学士学位和法学博士学位。来自康奈尔大学法学院。
Heidy King Jones joined Provention as its Chief Legal Officer "CLO" in August 2020. As Chief Legal Officer, Ms. King-Jones supports Provention Bio's commitment to upholding the best practices of compliance, corporate governance, and legal and enterprise risk management. Prior to joining Provention, Ms. King-Jones served as Senior Vice President and General Counsel of Axcella Health, Inc. where she worked from January 2018 to August 2020. Prior to Axcella, she held legal roles of increasing responsibility at Sarepta Therapeutics from July 2013 to January 2018 including head of Corporate Law Department and lead attorney for commercialization of Exondys 51. Ms. King-Jones started her career as a part of Ropes & Gray LLP's Securities & Public Company Practice Group. She holds a B.A. from Dartmouth College and a J.D. and LL.M. from Cornell Law School.